Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fondaparinux: a synthetic selective factor-Xa inhibitor.

Nina N Wong1

  • 1Department of Pharmacy, Montefiore Medical Center, Bronx, NY 10467, USA. nwong@montefiore.org

Heart Disease (Hagerstown, Md.)
|July 25, 2003
PubMed
Summary

Fondaparinux, a synthetic factor-Xa inhibitor, effectively prevents deep vein thrombosis after hip or knee surgery, showing greater efficacy than enoxaparin. However, a lack of a readily available antidote for overanticoagulation remains a concern.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tinzaparin.

Heart disease (Hagerstown, Md.)·2002
See all related articles

Area of Science:

  • Pharmacology
  • Thrombosis Research
  • Surgical Prophylaxis

Background:

  • Deep vein thrombosis (DVT) is a significant risk following major orthopedic surgeries.
  • Current antithrombotic agents have limitations in efficacy or safety profiles.
  • Fondaparinux represents a novel synthetic selective factor-Xa inhibitor.

Purpose of the Study:

  • To evaluate the efficacy and safety of fondaparinux for DVT prophylaxis in patients undergoing hip or knee surgery.
  • To compare the efficacy of fondaparinux with enoxaparin in this patient population.
  • To explore potential future applications of fondaparinux in other cardiovascular conditions.

Main Methods:

  • Clinical trials assessing fondaparinux for DVT prophylaxis.
  • Comparative analysis of fondaparinux versus enoxaparin efficacy.

Related Experiment Videos

  • Ongoing investigations into fondaparinux for treatment of DVT, unstable angina, and myocardial infarction.

    • Main Results:

    • Fondaparinux demonstrates superior efficacy compared to enoxaparin for DVT prophylaxis in hip/knee surgery patients.
    • It offers a safe and effective alternative to existing antithrombotic therapies.
    • Once-daily dosing is facilitated by its long half-life.

    Conclusions:

    • Fondaparinux is a highly effective agent for preventing DVT in orthopedic surgery patients.
    • Its efficacy surpasses that of enoxaparin, though cost and antidote availability are considerations.
    • Further research is exploring its utility in treating acute thrombotic and cardiovascular events.